Swedbank Robur Healthcare vs Proethos Fond

Swedbank Robur Healthcare vs Proethos Fond

1. Swedbank Robur Healthcare

  • Security

    Swedbank Robur Healthcare A

  • Fee

    1.30%

  • ISIN

    SE0000639445

  • Holdings

    25

2. Proethos Fond

  • Security

    Proethos Fond

  • Fee

    0.65%

  • ISIN

    SE0010547778

  • Holdings

    9

Fund Holdings

We have information about 28 holdings in Swedbank Robur Healthcare, where the largest holding is UnitedHealth (8.49), followed by Eli Lilly (8.12) and AstraZeneca (6.21). In comparison with Proethos Fond, we have 10 holdings where Storebrand Grön Obligation A SEK is the largest holding (8.78), followed by Vestas (6.18) and Shimano (5.4).

All Holdings

Here we compare the holdings in Swedbank Robur Healthcare and Proethos Fond.

Swedbank Robur Healthcare Proethos Fond
1. UnitedHealth Group Inc
USA
8.49 %
1. Storebrand Grön Obligation A SEK
Sweden
8.78 %
2. Eli Lilly and Co
USA
8.12 %
2. Vestas Wind Systems A/S
Denmark
6.18 %
3. AstraZeneca
Sweden UK
6.21 %
3. Shimano ADR
Japan
5.4 %
4. Novo Nordisk B
Denmark
5.78 %
4. First Solar Inc
USA
5.08 %
5. AbbVie Inc
USA
5.01 %
5. Nordex SE
Germany
4.8 %
6. Merck & Co Inc
Germany
4.71 %
6. Ormat Technologies Inc
USA
4.33 %
7. Thermo Fisher Scientific Inc
4.45 %
7. NIBE Industrier B
Sweden
4.32 %
8. McKesson Corp
USA
4.27 %
8. Central Japan Railway Co
Japan
4 %
9. Abbott Laboratories
USA
4.24 %
9. Enphase Energy Inc
USA
1.51 %
10. Danaher Corp
USA
4.03 %
-
11. Roche Holding AG
Switzerland
3.84 %
-
12. Boston Scientific Corp
3.73 %
-
13. Centene Corp
3.56 %
-
14. Vertex Pharmaceuticals Inc
3.28 %
-
15. Sanofi SA
France
2.96 %
-
16. HCA Healthcare Inc
2.76 %
-
17. Merck KGaA
Germany
2.19 %
-
18. Cooper Companies Inc
1.78 %
-
19. Edwards Lifesciences Corp
1.62 %
-
20. Takeda Pharmaceutical Co Ltd
Japan
1.55 %
-
21. Hologic Inc
1.43 %
-
22. IQVIA Inc
1.36 %
-
23. Royalty Pharma Plc
1.36 %
-
24. Halozyme Therapeutics Inc
0.91 %
-
25. ConvaTec Group Plc
0.83 %
-

The list of fund holdings was last updated on July 27, 2025.